Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hussayni, Samer Al
OPTIMAS, NCT03759938: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial	Active, not recruiting	N/A	3648	Europe	Direct oral anticoagulant (DOAC), dabigatran, apixaban, edoxaban, rivaroxaban	University College, London	Stroke, Acute, Atrial Fibrillation	05/24	10/24
Leaning, Darren
PACE-NODES, NCT05613023: A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT	Recruiting	3	1128	Europe, RoW	SBRT, SABR	Institute of Cancer Research, United Kingdom, Prostate Cancer UK	Prostate Cancer	06/28	06/30
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Elliott, Claire
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27
Keith, Sarah
ADAPT-P, NCT06019676: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients	Recruiting	N/A	170	Europe		Royal Marsden NHS Foundation Trust, Janssen, LP	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	04/27	04/27